



## Roche inks MoU with Delhi State Cancer Institute

12 February 2022 | News

### To strengthen cancer care treatment pathways and capabilities of healthcare professionals in DSCI

Roche Pharma India and Delhi State Cancer Institute (DSCI) have inked a Memorandum of Understanding (MoU) to strengthen the cancer care capabilities at DSCI and enable delivery of quality and comprehensive cancer care treatment for patients who get treated in the DSCI network.

The partnership will bolster and close the current gaps in cancer prevention and management across DSCI, enabling it to become a leader in Oncology care.

"Through this partnership, we look forward to improving patient treatment outcomes, and knowledge and skills of people involved in delivering cancer care in the DSCI network. PPP models like this enable us to expand our service delivery network by actively encouraging learning, participations and integration with other Delhi government hospitals said Satyendar Jain, Health Minister of Delhi.

The partnership between Roche and DSCI, initially for a period of 3 years, will focus on improving access to timely identification and innovative advanced treatment therapies for various cancers through capacity building and mentorship programs for oncologists at DSCI (East and West) in partnership national and international experts in Oncology.

It will also focus on establishing an educational Virtual Tumor Boards (VTBs) to standardize the management of complex oncology cases.

Commenting on this partnership, Roche Pharma Managing Director & CEO V. Simpson Emmanuel said, "Partnerships like the one with DCSI will help strengthen the overall cancer care delivery ecosystem in Delhi and ensure people have access to quality treatment options."

